Since 2019, we have been developing Prostate.Carcinoma.ai© to make PIRADS prostate screening easier, faster and safer.
This is what distinguishes our software:
Fully automatic 3D segmentation
Detection and segmentation of prostate lesions
Classification of prostate lesion
Supports DICOM standard for data transmission
MDR (EU) 2017/745 in 2023
Individual plugin for PACS and Viewer Workstations
Prostate.Carcinoma.ai© is available via licensing
Artificial intelligence for more efficiency in radiology
With an incidence of 1.4 million worldwide, prostate cancer and its detection make up a significant part of a radiologist's workload. With MRI scans of the prostate highly recommended prior to biopsy, capacity must be created to handle the increasing workload.
Artificial intelligence (AI) has the potential to take prostate cancer diagnostics to a new level, enabling faster, high-quality, and time-efficient diagnoses.
AI and machine learning technologies are facilitating reporting workflows by assisting in the diagnosis, management, and treatment of a wide range of conditions, including prostate cancer, in the shortest possible time.
Based on this knowledge, FUSE-AI has developed software that segments the prostate and its zones voxel by voxel and detects suspicious lesions.